Cancer Barriers and Immunotherapy: EMT, Tumor Microenvironment, and HER2 Targeted Therapy

Overview

In this biology lecture, the professor discusses cancer biology with a focus on barriers that prevent tumor formation and progression. The talk begins with the Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo for immune-based strategies to fight cancer, highlighting how releasing the immune \"brake\" can empower anti-tumor responses. The narrative then outlines core barriers such as regulated growth and survival signals, immune surveillance, basement membrane integrity, and the tumor microenvironment. A concrete example is HER2 positive breast cancer and the success of Herceptin, an antibody therapy that blocks signaling and recruits immune cells. The speaker also introduces epithelial to mesenchymal transition EMT as a pivotal step toward invasion, setting the stage for later immune-focused mechanisms.

Introduction and context

The lecture frames cancer as a progressive loss of tissue organization and introduces the Nobel Prize context for immune-based cancer therapy. It explains that Allison and Honjo were recognized for discoveries that free the immune system to attack cancer, a concept that will be revisited when immunology is covered in the course. The talk then transitions to barriers that normally keep cells from becoming malignant.

Barriers to tumorigenesis: growth, survival, and apoptosis

It describes growth and survival signals as gatekeepers of cell division. Oncogenic mutations and loss of tumor suppressors can push cells toward uncontrolled proliferation, but even then fail-safes like apoptosis often eliminate abnormal cells. The tumor microenvironment and signals from surrounding stromal cells can sustain tumor growth, showing that cancer cells remain partly dependent on external growth cues. The basal membrane and extracellular matrix create a physical barrier that cancer cells must breach to invade other tissues.

HER2 positive breast cancer and Herceptin

The talk highlights HER2 overexpression in about 30% of breast cancers, a hallmark of growth factor signaling dependence. Herceptin, a monoclonal antibody targeting HER2, revolutionized treatment by blocking signaling and recruiting immune cells to kill cancer cells, illustrating how targeted therapy can exploit the tumor's reliance on growth cues.

From epithelial to mesenchymal states: dismantling cell adhesion

A central transition is the epithelial to mesenchymal transition EMT, a program that reduces cell-cell adhesion and promotes migration. EMT is driven by master transcription factors like Twist, Snail, and Slug, originally studied in fly development where Twist-expressing cells invade the embryo to form muscle. In cancer, EMT is activated at the tumor-stroma boundary, illustrated by upregulation of integrins such as alpha beta at the interface, and is linked to increased motility and invasion. EMT is described as an epigenetic, reversible change rather than a simple mutation, enabling cancer cells to switch between stationary and invasive states as needed.

The tumor microenvironment and invasion dynamics

The lecture uses a tumor microenvironment concept to show how cancer cells recruit stromal cells that secrete growth and survival signals, reinforcing tumor growth. This mirrors wound healing, where similar EMT programs participate in closing wounds. The dynamic interaction between tumor cells and surrounding fibroblasts and immune cells creates a self-sustaining loop that supports tumor progression.

Actin dynamics and cell migration: the mechanics of movement

Moving from adhesion to movement, the talk details the cytoskeletal machinery that powers migration. Actin polymerization forms dense networks at the cell front producing a protrusive force. The plus end of actin grows at the leading edge while the minus end disassembles at the rear, driving a net forward movement. The cell attaches to the substrate via integrins at the leading edge, forming focal adhesions that transmit traction. The cycle of protrusion, adhesion, and pulling enables 2D migration, while in confined 3D environments cells can migrate with reduced reliance on integrins, a mode called chimneying.

Conclusion and implications for cancer therapy

Overall, the talk emphasizes that cancer progression involves multiple, overlapping barriers and that therapies can exploit these dependencies, whether through immunotherapy that harnesses immune surveillance or targeted therapies like Herceptin that block growth signals. By understanding EMT and the tumor microenvironment, researchers can better anticipate metastasis, design interventions, and interpret how normal developmental programs are co-opted in cancer.